|
The
Early Recognition and Management of Chronic Obstructive Pulmonary Disease
Index:
Introduction
COPD Definitions
and Pathogenesis
The
National Lung Health Education Program
Methods
of Smoking Cessation
Maintenance
Management of Symptomatic COPD
Treatment
of Advanced Disease
The
New Era
|
|
COPD Definitions and Pathogenesis
We are all aware of the high cost of smoking; however, approximately
45 million teenagers and adults continue to smoke. Fortunately,
teenagers are smoking less, and adults are quitting more. The anti-smoking
programs directed at elementary school-aged children need to continue.
We have not found an effective way to greatly reduce the initiation
of smoking by pre-teens and teenagers. Accordingly, more emphasis
needs to be placed on smoking cessation programs in early adulthood.
COPD is characterized by premature losses of ventilatory function as
judged by spirometry (FEV1). Whereas, the normal decline
in FEV1of a six-foot man averages about 25 ccs per year, the
accelerated decline of FEV1 on the pathway to symptomatic
COPD averages 80-100 ccs per year. COPD is a result of host risk
factors and environmental exposures. Of course, host risk factors
cannot be changed, but the control of smoking, air pollution and occupational
exposures can make a major difference in the course and prognosis of COPD.
COPD is not only a smokers’ disease that clusters in families,
but one that worsens with age. As we face an aging population, we
will have more and more patients with COPD.
COPD shares common factors with asthma. Both diseases have a familial
component; both are caused by inflammation that results in bronchospasm;
both are potentially reversible or progressive. Sometimes it is
difficult to separate asthma from COPD and, indeed, the diseases may coexist.
However, the pathogenesis of COPD is quite different from asthma
and involves macrophages, neutrophils, elastases, oxidants and CD8 lymphocytes.
The natural history of COPD covers 30-40 years. It begins with
biochemical and cellular events occurring at the tissue level, which quickly
attack small airways and surrounding alveoli. By the time clinical
and x-ray signs of COPD are present, the disease is far advanced. The
original attack is on the alveolar attachments of small airways that serve
to tether airways and maintain their patency. Alveolar lesions are
probably due, at least in part, to accelerated apoptosis of alveolar capillaries
caused by cigarette smoking. Thus the airways lesions are inflammatory
and bronchospastic, but alveolar lesions are ischemic.
Airflow abnormalities are measured by a spirometer and are key to the assessment
of all chronic pulmonary diseases, including COPD. Expiratory airflow
is a function of pressure against resistance. Thus, in COPD, airflow
is limited or reduced by loss of elastic recoil, airway narrowing, or both.
Simple office spirometers have been introduced in response to the
NLHEP and must be used for assessment and responses to therapy. The
Clinical Spectrum of COPD
COPD has had many definitions in the past. The clinical labels
of chronic bronchitis, asthmatic bronchitis and emphysema, and overlaps
of these individual components, are commonly used. COPD is an all
inclusive, non-specific term with chronic symptoms of cough, excess mucus
and exercise-related dyspnea. COPD is characterized by a progressive
reduction in airflow that is not fully reversible with broncho-active
drugs. Hyperinflation is common.
Signs and symptoms in the early stages of COPD are often absent or ignored
by both the patient and the healthcare workers Chest x-ray or EKG
abnormalities are also not seen during the early stages of COPD.
Spirometry
Spirometry should be looked upon as a simple expression of a complex
process just as with blood pressure. All primary care physicians
need to understand the essence of spirometry, and this can be easily taught.
The lungs are filled by muscular effort, and in the normal state,
there is a uniform distribution of ventilation. Expiratory airflow
is a function of muscular force, elastic recoil, large airways function,
small airways function and interdependence. Conventional spirometry
measures volume over time. A second convention measures flow over
volume. Both expressions measure exactly the same thing but express
it in a different way. NLHEP recommends only two parameter spirometry,
(i.e., FEV1, FVC and the ratio between the two). The
normal ratio is greater than 70%. Since normal lungs empty in six
seconds or less, the FEV6 has become the surrogate for
FVC.
FEF 25-75% and other “nonsense numbers” should be eliminated.
These tests do not measure small airways disease and are often misleading.
Whereas, no reasonable doctor would prescribe insulin without measuring
blood sugar, use antihypertensives without measuring blood pressure, treat
cardiac arrhythmias without EKG evidence, or use Coumadin without measuring
international neutralization ratio (INR), many physicians still continue
to use powerful bronchoactive drugs, including corticosteroids, without
spirometric documentation. In fact, this sometimes leads to lawsuits
when steroid complications occur.
The concept of lung age can be understood by patients. Normal lung
age is that age for which a patient’s lung function is normal. Thus,
a patient may have a reasonable pulmonary function at age 45, (say an
FEV1 of 2.5 liters), but this is actually the normal lung
function for a patient 70 years old! This means that this 45 year-old
has a ‘lung age’ of 70. This fact may gain a patient’s
attention and help to motivate him/her to initiate a smoking cessation
attempt.
BACK
TO TOP
|